The mRNA-based vaccines that turned the tide of the COVID-19 pandemic currently account for almost all the value of the mRNA vaccine/therapeutic market. Indeed, the vaccine-led response to the ...
TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...
RNA, widely known from the COVID-19 vaccine, is not actually a "therapeutic agent," but a technology that delivers the ...
SEOUL, South Korea--(BUSINESS WIRE)--Lemonex Inc., a biotechnology company developing innovative messenger RNA (mRNA) and siRNA therapeutics based on a novel nanoparticle drug delivery system ...
The mRNA synthesis and manufacturing market's potential lies in the increasing demand for mRNA therapeutics and vaccines, driven by COVID-19 successes. Opportunities include mRNA custom synthesis and ...
The MarketWatch News Department was not involved in the creation of this content. -- GEMORNA is world's first generative AI platform purpose-built for mRNA design and optimization, demonstrating state ...
Moderna Inc MRNA provided an update on regulatory submissions for the mRNA-1345 vaccine to prevent RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease in adults ...
STONY BROOK, NY / ACCESSWIRE / August 23, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the filing with the ...
Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results